1. Home
  2. VSTS vs ALVO Comparison

VSTS vs ALVO Comparison

Compare VSTS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$9.25

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo Alvotech

ALVO

Alvotech

HOLD

Current Price

$3.65

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
ALVO
Founded
1936
2013
Country
United States
Luxembourg
Employees
N/A
1460
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
VSTS
ALVO
Price
$9.25
$3.65
Analyst Decision
Sell
Buy
Analyst Count
4
4
Target Price
$5.88
$8.00
AVG Volume (30 Days)
997.5K
532.2K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,734,839,000.00
N/A
Revenue This Year
N/A
$12.28
Revenue Next Year
$1.67
$21.29
P/E Ratio
N/A
$18.20
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$3.03
52 Week High
$9.80
$11.85

Technical Indicators

Market Signals
Indicator
VSTS
ALVO
Relative Strength Index (RSI) 75.88 49.60
Support Level $7.24 $3.03
Resistance Level $9.80 $3.93
Average True Range (ATR) 0.32 0.21
MACD 0.15 0.06
Stochastic Oscillator 97.47 67.46

Price Performance

Historical Comparison
VSTS
ALVO

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

Share on Social Networks: